SGLT2 inhibition lowers lub raum pib rau cov piam thaj tso tawm, ua rau lub raum glycosuria, hloov pauv hauv substrate siv los ntawm carbohydrate rau roj oxidation thiab hyperglucagonemia; Qhov no ua rau muaj kev pheej hmoo rau ketoacidosis (xws li euglycaemic ketoacidosis) nyob rau hauv muaj lwm yam precipitating …
Yuav SGLT2 ua rau DKA?
Sodium-glucose cotransporter 2 (SGLT2) inhibitors yog txuam nrog yuav luag 3-fold nce kev pheej hmoo ntawm ntshav qab zib ketoacidosis(DKA) hauv qee cov neeg mob ntshav qab zib hom 2 (T2D), raws li cov ntaub ntawv los ntawm kev tshawb nrhiav kev tshawb fawb rov qab luam tawm hauv Annals of Internal Medicine.
Vim li cas SGLT2 inhibitors nce LDL?
Cov ntsiab lus-Peb cov kev tshawb fawb hauv cov kab mob ntshav qab zib CETP-ApoB100 cov nas hloov pauv hloov pauv ntau qhov kev hloov pauv hauv cov lipids pom nrog SGLT2 inhibition therapy hauv tib neeg thiab qhia tias nce LDL cov roj cholesterol pom nrog txoj kev kho no yog vim yog txo qhov kev tshem tawm ntawm LDL los ntawm kev ncig thiab ntau dua lipolysis…
Vim li cas dapagliflozin ua rau DKA?
Ntxiv rau, SGLT-2 inhibitors ua rau kom cov acetoacetate reabsorption hauv lub raum tubules, uas ua rau cov ntshav nce qib ntawm ketone lub cev. Qhov xwm txheej ntawm DKA cuam tshuam nrog dapagliflozin tau tshaj tawm tias yog <0.1%, tab sis cov lus ceeb toom ntawm DKA cuam tshuam nrog SGLT-2 inhibitors tau nce tsis ntev los no.
Farxiga ua rau ketoacidosis li cas?
Txawm tias tsis tshua muaj tshwm sim, qee cov neeg uas noj Farxiga tuaj yeem tsim qhov mob hnyav hu ua ntshav qab zib ketoacidosis. Tus mob no tshwm sim thaum lub hlwb ntawm koj lub cev tsis tau txais cov piam thaj uas lawv xav tau lub zog. Hloov chaw, koj lub cev siv rograu lub zog, uas tuaj yeem ua rau muaj tshuaj lom neeg hauv koj cov ntshav hu ua ketones.
